Skip to content 
Ready to turn inspiration into action? Explore our services now and transform your vision into reality with our expert assistance.
Proposing Evidence-Based Change
ACD is a severe inflammatory skin disease that is directly related to one’s contact with specific allergens and chemical products. It falls under type IV hypersensitivity or delayed type hypersensitivity and is one of the major carriers of occupational and environmental diseases. ACD can be attributed to acquired and inborn attributes – dermal diseases before the application of the irritant or hereditary characteristics concerning the skin (Nassau & Fonacier, 2020). The nurse’s role in the patient with ACD entails offering skin care and topical treatments, educating the patient on allergens, and acknowledging their emotional status (Thyssen et al., 2022). ACD is not a life-threatening ailment, and if treated correctly and with optimum medical care, NURS FPX 6218 Assessment 1 patient’s standard of living can improve. Given the circumstances, the management of ACD requires consideration of the means from outside the American healthcare system.
Executive Summary
NURS FPX 6218 Assessment 1 Proposed Change
The institution needs to improve the conditions pertaining to healthcare given to patients with ACD; thus, there is a need to make some changes. Regarding primary interventions, the patient is educated about the nature of the disease, and they are in a position to determine what causes their allergies and then make behavioral changes in order to reduce the inflammatory response of the disease. People with synthetic rubber allergies should select gloves that have a rubber accelerator that does not affect them, such as carbamates or any other substance (Dejonckheere et al., 2019).
The most effective treatment for ACD is the identification and subsequent eradication of the agents that result in the condition. NURS FPX 6218 Assessment 1 management of nurses with severe acute allergic contact dermatitis can, at times, be controlled with antihistamines and dermal or oral steroids. In this situation, complete elimination of the allergen from the patient’s environment is the only critical intervention to be taken in order to prevent repetition of the same (Lipman & Tosti, 2021).
ACD has a severely disabling effect on quality of life, as evidenced by the fact that when it occurs in defined areas of the body, its effect is enormous. Early identification of ACD patients has been shown to be more effective. The severity of ACD tends to vary, and this has been proven through various research. This is an emergent concern for everyone, especially health practitioners all over the world (Ahlström et al., 2019).
Expectations
It is significant to note that knowing how a disease works does translate into altering patient behavior. Thus, it is vital to address factors such as growth stage, prior knowledge, and previous interaction with experts to motivate the person to act better. Due to these reasons, this approach is said to have a higher yield than the other one.
Procedures should be clearly described to improve healthcare and demonstrate to people how to prevent allergic contact dermatitis. This, therefore, encompasses sensitizing people to the condition, the origin of the allergic response, the resultant effects or signs, and the ideal line of treatment. Healthcare practitioners should educate their patients about the necessity of protective clothing and/or shields and non-chemical skin care products to avoid future episodes (Uter et al., 2020).
NURS FPX 6218 Assessment 1 Desirable Outcomes
The objectives of the interdisciplinary team of an institution are focused solely on the optimization of patients’ outcomes. The physician may then resort to giving treatment if the situation calls for it. However, it is advised that one consult a pharmacist on the type of drug to take as well as the proper dosage. First and foremost, the treatment must be personalized with regards to the specific patient as well as the particular body part that has been affected, and then expand on the educational components, finally having constant contact with other specialists in the field.
Limiting Factors
Several challenges hinder the realization of the intended objectives in managing ACD, of which health costs are increasing in the United States. The cost of managing ACD is, however more aggravated by the fact that most insurance carriers in the health folds do not wholly assume the account. Hence, the patient is burdened. These are considered to be burdensome to patients, especially those with less capability to raise the amount of cash needed (Herman et al., 2021).
Who will Pay for the Care?
Thus, the final expenses for ACD treatment remain at the patient level since they undergo all essential diagnostic measures and pay for the corresponding therapies and medications. Such costs can become a real problem for people who do not have health insurance because they simply cannot afford it. Also, the inability to have insurance often means a delay in the disease’s detection and treatment, and as a result, the disease progresses and costs more money.
The Rationale for the Proposed Change
The particular modifications that can be employed may also be helpful in ACD patients’ cases because it is usually less severe and less frequent in terms of allergens’ symptoms. For example, through avoiding contact with allergens that trigger ACD, some of the inflammation and, thus, soreness that accompanies the condition can be subsided. Besides, the timely identification of ACD patients and subsequent implementation of training and informative sessions can facilitate the modulation of therapy and the speed of skin recovery, which would undoubtedly enhance patients’ quality of life (Ahlström et al., 2019).
The mentioned outcomes are expected to include a lessening of ACD symptoms’ intensity and frequency, enhanced treatment results, and a better quality of life. Research like the NIH study can justify such improvements, as early detection of the allergy and subsequent avoidance of contact with the allergen can help minimize inflammation and discomfort of ACD.
Financial and Health Implications
Implementing such changes for a better Health outcome for ACD patients could have fiscal and health risks. Most of the interventions aimed at increasing the early detection of patients with ACD, for instance, the provision of patch testing, will prove to result in low costs of treating this condition. NURS FPX 6218 Assessment 1 detected early, it can be well managed, and expensive treatments like antihistamines or corticosteroids are not often required. It also enables the patient to go for treatment and take all the necessary measures to minimize the intensity of the symptoms. This could improve their obviously distressed quality of life in addition to drastically decreasing the exorbitant costs associated with chronic therapies (Herman et al., 2021).
On the other hand, failure to make the cost changes as proposed can have significant financial and health consequences. In the case of ACD, if not detected early and treated well, it progresses to a higher level where more intensive therapies like systemic steroids have to be applied. Thus, it could mean increased expenses and the accumulated bill on the part of the individual as well as the larger healthcare agenda. Furthermore, the failure to diagnose such a condition early may affect the patient’s quality of life, as this often becomes a serious hindrance to working and even carrying out simple tasks. Goldenberg et al. ’s (2020) cross-sectional study conducted in the United States revealed that where patch testing was made available, NURS FPX 6218 Assessment 1 managing cost of ACD was reduced by considerable figures. Further, it was observed that patients who received patch testing had a significantly lower number of symptoms than the other patients who didn’t receive patch testing and had a higher quality of life.
Conclusion
In NURS FPX 6218 Assessment 1 presented alterations to improve the quality of health of ACD patients can have quantitative as well as qualitative consequences. Based on the research done, they are capable of enhancing the part costs of taking care of needy people with ACD, and at the same time. In that regard, all three countries have outlined ways of early diagnosis of ACD, potential allergens and toxins, and support measures for patients suffering from the ailment. It is worth mentioning that the above-stated strategies can be effective in decreasing the cost of treating ACD and increasing satisfaction among patients. Thus, it can be assumed that the effects of making these discussed changes enhance ACD with better patients’ health, which is likely to be both financially and health-wise beneficial.
References
Dejonckheere, G., Herman, A., & Baeck, M. (2019). Contact Dermatitis, 81(3), 167–173. https://doi.org/10.1111/cod.13269
Goldenberg, A., Ehrlich, A., Machler, B. C., & Jacob, S. E. (2020). Patch test clinic start-up. Dermatitis, 1. https://doi.org/10.1097/der.0000000000000559
Gopinath, H., Karthikeyan, K., & Meghana, V. (2020). Indian Journal of Dermatology, Venereology and Leprology, 86(6), 622. https://doi.org/10.4103/ijdvl.ijdvl_402_19
Health risks associated with arsenic contamination and its biotransformation mechanisms in the environment: A review. Emerging Contaminants and Associated Treatment Technologies, 241–288. https://doi.org/10.1007/978-3-030-96523-5_11
Khan, F. A., Rohatgi, S., Nirhale, S., Manohar, P., Rao, P., Naphade, P., Dave, D., Sravya Kotaru, V., Gupta, S., Gitay, A., & Dubey, P. (2022). Annals of African Medicine, 21(3), 296. https://doi.org/10.4103/aam.aam_260_21
Krpata, D. M. (2019). Wound Closure and Management. Surgical Infections, 20(2), 135–138. https://doi.org/10.1089/sur.2018.235
Lampel, H. P., & Powell, H. B. (2019). Occupational and Hand Dermatitis: A practical approach.
Michaelis, L. J., Skypala, I. J., Gardner, J., Sheikh, A., Fox, A. T., & Holloway, J. A. (2019). Upskilling healthcare professionals to manage clinical allergy. Clinical & Experimental Allergy, 49(12), 1534–1540. https://doi.org/10.1111/cea.13497
Murphy, P. B., Hooten, J. N., Atwater, A. R., & Gossman, W. (2019). Allergic contact dermatitis. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532866/
Nassau, S., & Fonacier, L. (2020). Allergic contact dermatitis.
NICE. (2019). Dermatitis – contact | National Institute for Health and Care Excellence. https://cks.nice.org.uk/topics/dermatitis-contact/
